Global equity markets are on edge amid uncertainty in the Middle East, compounded by economic growth concerns.
Keep Reading →
June 30 - Dividend Stocks, Hedge Funds, News
Dividend stocks have remained a popular choice for investors over the years. They offer the potential for long-term returns while providing a steady stream of income.
Keep Reading →
June 28 - Dividend Stocks, Hedge Funds, News
AbbVie Inc. (NYSE:ABBV) is one of the top trending US stocks to buy now. AbbVie Inc.
Keep Reading →
June 27 - News
Profitability is being watched more closely as investors look beyond headline earnings and ask how efficiently companies turn shareholder capital into profits.
Keep Reading →
June 26 - Hedge Funds, News
On June 18, Tom Lee, Fundstrat's Managing Partner and Head of Research, appeared on CNBC's ‘Closing Bell’ to discuss where stocks are headed from Thursday’s levels.
Keep Reading →
June 25 - Hedge Funds, News
Dividend stocks have also trailed the broader market this year. However, the gap has been relatively narrow.
Keep Reading →
June 24 - Dividend Stocks, Hedge Funds, News
Dividend Kings have earned a strong following among income investors because they have proven their ability to raise their dividends through different market cycles.
Keep Reading →
June 22 - Dividend Stocks, Hedge Funds, News
High-quality stocks are getting more attention as investors look for companies that can keep growing earnings without depending only on market momentum.
Keep Reading →
June 20 - Hedge Funds, News
Counter-cyclical stocks are getting more attention as investors look for businesses tied to demand that does not disappear just because the economy slows.
Keep Reading →
June 16 - Hedge Funds, News
Is ABBV a good stock to buy? We came across a bullish thesis on AbbVie Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on ABBV.
Keep Reading →
June 11 - News, Stock Analysis
AbbVie Inc. (NYSE:ABBV) is one of the best cheap stocks to buy for beginners. AbbVie Inc.
Keep Reading →
June 5 - News
On June 2, Ben Snider, chief U.S.
Keep Reading →
June 4 - Hedge Funds, News
AbbVie Inc. (NYSE:ABBV) is one of the top 10 undervalued blue chip stocks analysts recommend for smart investing. AbbVie Inc.
Keep Reading →
June 2 - News
TheFly reported on May 27 that ABBV announced FDA approval of DECNUPAZ (pivekimab sunirine-pvzy) for adults diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), ...
Keep Reading →
June 2 - News
Jamie Dimon commented on May 29 at the Reagan National Economic Forum that the market is exuberant but not bad.
Keep Reading →
May 31 - Hedge Funds, News
Despite growing geopolitical tensions related to the Iran war, Callanish Capital CEO Haig Bathgate shared an optimistic stance on global markets during an appearance on CNCB on...
Keep Reading →
May 31 - Hedge Funds, News
AbbVie Inc. (NYSE:ABBV) ranks among the best retirement stocks to buy now. Piper Sandler increased its price target for AbbVie Inc.
Keep Reading →
May 27 - News
A great many people struggle to determine how much money they will need to live comfortably in retirement, especially as retirement expenses rise annually.
Keep Reading →
May 25 - Hedge Funds, News
On May 13, Sébastien Page of T.
Keep Reading →
May 22 - Hedge Funds, News
US stocks have advanced to record highs while shrugging off the lack of resolution in the US-Iran war and concerns over soaring inflation.
Keep Reading →
May 20 - Hedge Funds, News
Morningstar Chief US Market Strategist David Sekera wrote, “Stocks are undervalued, but for a reason,” in his Q2 2026 stock market outlook.
Keep Reading →
May 19 - Dividend Stocks, Hedge Funds, News
In this article, we will discuss: Jim Cramer Revealed His Big AI Investing Fear & & Discussed These 20 Stocks.
Keep Reading →
May 13 - News
AbbVie Inc. (NYSE:ABBV) is one of the best healthcare stocks to buy for the long term. AbbVie Inc.
Keep Reading →
May 12 - News
On May 7, Haig Bathgate, CEO of Callanish Capital, appeared on CNCB to talk about his bullish view on the global markets amid the Iran war, and how its impact would be short-lived...
Keep Reading →
May 10 - Hedge Funds, News
On May 7, Fundstrat’s Tom Lee joined 'Closing Bell' on CNBC to discuss his outlook on the current stock market rally.
Keep Reading →
May 7 - Hedge Funds, News
AbbVie Inc. (NYSE:ABBV) is one of the best drug stocks to buy according to analysts. AbbVie Inc.
Keep Reading →
May 1 - News
Dividends don’t always get much attention, but they’ve quietly driven a large share of long-term returns.
Keep Reading →
April 30 - Dividend Stocks, Hedge Funds, News
Operator: Good morning, and thank you for standing by. Welcome to the AbbVie First Quarter 2026 Earnings Conference Call.
Keep Reading →
April 30 - News, Transcripts
Retail investors have taken center stage in 2026. Scott Rubner of Citadel Securities noted that trading activity from individual investors hit a record in January.
Keep Reading →
April 27 - Dividend Stocks, Hedge Funds, News
AbbVie Inc. (NYSE:ABBV) is one of the best stem cell therapy stocks to buy. On April 23, Piper Sandler cut the price target on AbbVie Inc.
Keep Reading →
April 27 - News
AbbVie Inc. (NYSE:ABBV) is one of the best low volatility stocks to invest in right now. AbbVie Inc.
Keep Reading →
April 27 - News
On April 23, Peter Boockvar, One Point BFG Wealth Partners CIO, appeared on CNBC’s ‘Fast Money’ to talk about the market dynamics.
Keep Reading →
April 25 - Hedge Funds, News
On April 23, Bankim Chadha, chief global strategist at Deutsche Bank, appeared on CNBC's ‘Money Movers’ to talk about uncertainty in the markets and what to expect with the...
Keep Reading →
April 25 - Hedge Funds, News
It’s been a turbulent year for the S&P 500 amid heightened volatility, driven by monetary policy uncertainty and inflationary concerns, and exacerbated by geopolitical tensions...
Keep Reading →
April 22 - Hedge Funds, News
Pullbacks tend to create favorable setups when they hit more than just the weakest parts of the market.
Keep Reading →
April 22 - Hedge Funds, News
AbbVie Inc. (NYSE:ABBV) is one of the 10 Best Major Stocks to Buy According to Wall Street Analysts.
Keep Reading →
April 20 - News
The Mag 7 stocks, with their stretched valuations and lackluster 1-year performance, have recently gone out of favor among both analysts and the general public.
Keep Reading →
April 19 - Hedge Funds, News
On April 2, CNBC reported that while stocks often provide strong long-term growth despite short-term swings, a prolonged market downturn close to retirement can create real challenges...
Keep Reading →
April 15 - Dividend Stocks, Hedge Funds, News
An April 8 report from CNBC pointed out that dividend yields are not what they used to be, so investors need to be more selective with their choices.
Keep Reading →
April 9 - Dividend Stocks, Hedge Funds, News
The AdvisorShares Psychedelics ETF, a fund that primarily invests in the psychedelic drugs sector, is up 31% over the past year.
Keep Reading →
March 24 - Hedge Funds, News
Equity income is getting harder to find. The Morningstar US Market Index had a dividend yield of under 1.2% in the first quarter of 2026.
Keep Reading →
March 19 - Dividend Stocks, Hedge Funds, News
AbbVie Inc. (NYSE:ABBV) is a constant part of the 13F portfolio of Fisher Asset Management since the start of 2013.
Keep Reading →
March 17 - News
AbbVie Inc. (NYSE:ABBV) is one of Goldman Sachs top healthcare stocks. On March 9, William Blair reiterated an Outperform rating on AbbVie Inc. (NYSE:ABBV).
Keep Reading →
March 16 - News
For many Wall Street investors, it is their first time navigating market uncertainty at a time of geopolitical upheaval.
Keep Reading →
March 16 - Hedge Funds, News
Is ABBV a good stock to buy? We came across a bullish thesis on AbbVie Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on ABBV.
Keep Reading →
March 15 - News, Stock Analysis
The healthcare sector, long seen as a laggard amid the artificial intelligence boom, is beginning to turn the corner.
Keep Reading →
March 14 - Hedge Funds, News
AbbVie Inc. (NYSE:ABBV) is one of the debt free halal stocks to buy. On March 3, at the TD Cowen 46th Annual Health Care Conference, AbbVie Inc.
Keep Reading →
March 13 - News
Jitters in the US equity market are rising as concerns about artificial intelligence, a looming software-as-a-service downturn, and ongoing conflict in the Middle East unsettled...
Keep Reading →
March 13 - Hedge Funds, News
On February 24, RBC Capital began coverage of AbbVie Inc. (NYSE:ABBV) with an Outperform rating and a price target of $260.
Keep Reading →
March 12 - News